International Day of Women in Science
On the occasion of the 2026 International Day of Women in Science, taking place each year in February 11th, we proudly spotlight Eva Potthoff, MSAT Circle Lead at ten23 health.
Scientific problem solving in action
Here, we share insights, updates, and perspectives from across our company—from scientific innovation and sustainability to team culture and industry trends. Get a deeper look at how we think, work and grow at ten23 health, always guided by our purpose of serving Patients, People and the Planet by helping develop and deliver better therapies.
On the occasion of the 2026 International Day of Women in Science, taking place each year in February 11th, we proudly spotlight Eva Potthoff, MSAT Circle Lead at ten23 health.
In 2025, the US FDA has approved 46 novel drugs that year. Amongst those, 12 biologics—accounting roughly 25% of total approvals—include antibody-drug conjugates (ADCs), fusion proteins, and both mono- and bispecific monoclonal antibodies. While oncology remained the primary focus for the approved biologics, recent approvals also span a diverse range of therapeutic areas, including pulmonary, cardiovascular, renal, immunology, and neurology.
The article highlights how CMC has become a strategic priority in biotech, especially for sterile drug products. It explains the risks of poor CMC planning and shows how ten23 health enables regulatory, manufacturing, and investor confidence.
Integrated development improves speed, quality, and scalability in drug production. This article highlights how ten23 health streamlines the entire process—from molecule characterization to commercial manufacturing—under one roof.
Pre-filled syringes play a key role in modern biologics. This case study explores how ten23 health resolved formulation challenges to ensure safe and stable drug delivery.
In today’s post you can learn about how it is to work at ten23 health and which methods we use for career development and personal growth.
Looking for a partnership powered by purpose?
We're ready for what comes next.